Reneo Pharmaceuticals, Inc. (RPHM)
|Address:12230 El Camino Real
San Diego, CA 92130
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP).
Reneo Pharmaceuticals is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
We are initially developing REN001 in three rare genetic diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease).
We completed an open-label Phase 1b clinical trial in patients with PMM and, based on the results, initiated a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial in patients with PMM and plan to begin enrollment in the first half of 2021.
We are also conducting two open-label Phase 1b clinical trials of REN001 in patients with LC-FAOD and with McArdle disease and we anticipate results in the first half of 2022.
We also plan to explore the potential of REN001 in other rare diseases, such as Duchenne muscular dystrophy and Alport syndrome.
|Michael G. Grey||Founder and Executive Chairman|
|Gregory J. Flesher||President, Chief Executive Officer and Director|
|Vineet R. Jindal||Chief Financial Officer|
|Deborah J. Tower||Vice President of Finance and Administrative|
|Wendy S. Johnson||Chief Development Officer|
|Dr. Alejandro Dorenbaum||Chief Medical Officer|
|Michael Cruse||Senior Vice President of Corporate Operations|